Drug intelligence / Profile preview

VG102

Development stage: Preclinical
Lead developer: Genesis Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

VG102 is an anti-CD55 antibody developed for the treatment of cancer, specifically metastatic cancer. It was acquired by Genesis Biopharma from Hamilton Atlantic as part of its strategic transformation into a biopharmaceutical company. Genesis Biopharma also secured an exclusive, worldwide license from Cancer Research Technology (CRT) for intellectual property related to the therapeutic use of anti-CD55 antibodies, which is essential for the development of VG102.

Other names: Anti-CD55 Antibody ProgramAnti-CD-55 Antibody ProgramAnti-CD 55 Antibody Program

Targets

CD55 (Complement decay-accelerating factor)

Beyond the preview

Go deeper on VG102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VG102.

Explore the full profile